Stable Isotope-Labeled Synthetic Intermediates
In recent years some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing non-deuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring. With the largest deuterated intermediate production capacity in the world we are able to supply all scales from research to commercial production. If this in an area of interest for you then please don’t hesitate to contact us to discuss you needs.
The potential advantages of deuterated pharmaceuticals:
Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.
Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track allowing more of the unmetabolized drug to reach its target.
Increased half-life. Deuterated compounds can have a slower pharamacokinetic affect extending the absorption and distribution in the body. This may decrease the number of doses that a patient may require in certain time period compared to its non-deuterated counterpart.
| Catalog No. | Description |
| DLM-112 | Acetaldehyde (D4, 99%) |
| DLM-12 | Acetic acid-d4 (D, 99.5%) |
| DLM-1556 | Acetic acid (OD, 98%) |
| DLM-1162 | Acetic anhydride (D6, 98%) |
| DLM-9 | Acetone-d6 (D, 99.9%) |
| DLM-247 | Acetyl chloride (D3, 98%) |
| DLM-855 | Acrylic acid (+ 0.1% 4-methoxyphenol) (2,3,3-D3, 98%) <5% H2O |
| DLM-862 | Aniline (ring-D5, 98%) |
| DLM-1 | Benzene-d6 (D, 99.5%) |
| DLM-494 | Biphenyl (D10, 98%) |
| DLM-1315 | Borane (D3, 98%) (1 molar in THF) (+0.005M NaBD4) |
| DLM-4747 | Borane methylsulfide complex (D3, 99%) |
| DLM-398 | Bromobenzene (D5, 99%) |
| DLM-874 | Bromoethane (D5, 98%) |
| DLM-181 | 1,4-Butanediol (2,2,3,3-D4, 98%) |
| DLM-1664 | tert-Butanol (D10, 98%) |
| DLM-1116 | tert-Butyl chloride (D9, 98%) |
| DLM-263 | Chlorobenzene-d5 (D, 99%) |
| DLM-337 | Chlorobenzene (D3, 99%) |
| CNLM-7289 | Cyanamide (13C, 99%; 15N2, 98%) (stabilized with <0.1% acetic acid) |
| DLM-1560 | Cyclohexanone (D10, 98%) |
| DLM-2781 | Cyclopentyl bromide (D9, 98%) |
| DLM-1003DR | Deuterium (D, 99.96) <400 PPM HD |
| DLM-408DR | Deuterium (D, 99.8%) (D2, 99.6% + HD, 0.4%) |
| DLM-458DR | Deuterium chloride (D,99%) |
| DLM-3 | Deuterium chloride (D, 99.5%) DCl 35% w/w solution in D2O |
| DLM-2 | Deuterium chloride (D, 99.5%) DCl 20% w/w solution in D2O |
| DLM-4DR | Deuterium oxide (D, 99.9%) |
| DLM-4-99 | Deuterium oxide (D, 99%) |
| DLM-4DR-99.8 | Deuterium oxide (D, 99.8%) |
| DLM-195 | 1,2-Dibromoethane-d4 (D, 99%) |
| DLM-158 | 1,2-Dichlorobenzene-d4 (D, 99%) |
| DLM-3903 | Dimethyl carbonate (D6, 99%) |
| DLM-196 | Dimethyl sulfate (D6, 98%) |
| DLM-10 | Dimethyl sulfoxide-d6 (D, 99.9%) |
| DLM-25 | N,N-Dimethylformamide-d7 (D,99.5%) |
| DLM-1670 | N,N Dimethylformamide (formyl-D, 98-99%) |
| DLM-31 | Ethanol-d6 (D, 99%) anhydrous |
| DLM-16 | Ethanol-d (D, 99%) <6% D2O |
| DLM-9660 | N-Ethylaniline (D10, 98%) |
| DLM-9626 | N-Ethylaniline (ethyl-D5, 98%) |
| DLM-347 | Ethylene (D4, 98%) |
| DLM-805 | Formaldehyde (D2, 98%) (~20% w/w in D2O) |
| DLM-286 | Formic acid (D2, 98%) <5% D2O |
| DLM-743 | Formic acid (formyl-D, 98%) <5% H2O |
| DLM-423 | n-Heptane (D16, 98%) |
| DLM-1023 | Iodoethane (1,1-D2, 98%) + copper wire |
| DLM-1024 | Iodoethane (2,2,2-D3, 98%) + copper wire |
| DLM-272 | Iodoethane (D5, 99%) + copper wire |
| DLM-44 | Isopropanol-d8 (D, 99%) |
| DLM-6201 | a-Ketoglutaric acid (3,3,4,4-D4, 98%) CP 90% |
| DLM-1945 | bis(2-Chloroethoxy) methane (chloroethoxy-D8, 98%) |
| DLM-1981 | Methanesulfonic acid (D4, 97-98%) |
| DLM-24RG | Methanol-d4 (D, 99.5%) |
| DLM-15 | Methanol-d (D, 99%) |
| DLM-651 | Methyl formate (formyl-D, 99%) |
| DLM-362 | Methyl iodide + copper wire (D3, 99.5%) |
| DLM-9707 | Methyl methanesulfonate (O-methyl-D3, 98%) |
| DLM-1500DR | Methylamine (D3, 98%) |
| DLM-289 | Methylamine·HCl (methyl-D3, 98%) |
| DLM-3484 | Morpholine (2,2,3,3,5,5,6,6-D8, 98%) |
| DLM-295 | 2-Nitrophenol (ring-D4, 98%) |
| DLM-296 | 4-Nitrophenol (ring-D4, 98%) |
| DLM-619 | Octanoic acid (D15, 98%) |
| DLM-300 | Paraformaldehyde (D2, 99%) |
| DLM-370 | Phenol (D6, 98%) |
| DLM-788 | Phthalic anhydride (D4, 98%) |
| DLM-9813 | Pivalic acid (trimethyl-D9, 98%) |
| DLM-9662 | Pyrrolidine (2,2,3,3,4,4,5,5-D8, 98%) |
| DLM-226 | Sodium borodeuteride (D4, 99%) CP 90-95% |
| DLM-45DR | Sodium deuteroxide (D, 99.5%) 40% in D2O |
| DLM-1361 | Sodium formate (D, 98%) |
| DLM-8206 | Sodium 2,2-dimethyl-2silapentane-5-sulfonate (DDS) (D6, 98%) |
| DLM-33DR | Sulfuric acid-d2 (D, 99%) 96-98% in D2O |
| DLM-36 | Tetrahydrofuran-d8 (D, 99.5%) |
| DLM-2729 | Tetramethylsilane (D12, 98%) |
Synthetic Intermediates for Deuterated Pharmaceuticals
Product Search
Got a Question?
For information please start your enquiry below: